AI allows patients, doctors, and payers to make informed decisions based on evidence at a much faster pace.
Nancy Dreyer
Advertisement
Articles by Nancy Dreyer
Personalized medicines often come to market without much safety information. Small populations mean less data. Genzyme, for example, received FDA approval for Cerezyme, to treat Gaucher disease, based on a pivotal trial with only 30 patients.
Advertisement
Latest Updated Articles
Personalized Medicine Meets the Real WorldPublished: June 1st 2006 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Bayer’s Lynkuet as First Dual Neurokinin Antagonist for Menopausal Hot Flashes
2
TrumpRx and the Dawn of Direct-to-Consumer Commercialization
3
Direct-to-patient: pharma’s next power move
4
AI Becomes Pharma’s New Operating System: Q&A with causaLens’ CEO and Co-Founder Darko Matovski
5
